Organon & Co.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-34.1% vs price
Base Case (Median)
16.7% vs price
Bull Case (75th pct.)
141.4% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-225.08 | -1743.0% | High (40%) |
| PE Comparable | $17.14 | 25.1% | Medium (25%) |
| Graham Number | $7.09 | -48.3% | Medium (40%) |
| EV/EBITDA | $49.42 | 260.7% | Medium (20%) |
| EV/FCF | $38.38 | 180.2% | Medium (20%) |
| Earnings Power Value | $14.85 | 8.4% | Medium (50%) |
Based on 6 out of 8 methods, OGN appears fairly valued at the current price of $13.70. The base case fair value of $15.99 implies 16.7% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.